Antibiotic resistance is no doubt one of the most serious threats in global healthcare system. The phenomenon has been led to tens of hundreds of deaths in recent years. Worryingly, the numbers are slated to grow in the coming years. The effectiveness of current therapies has declined with the rapidly growing threat of bacteria that have become immune to antibiotics. A team of researchers has flagged the mounting concern by looking at the threat of resistance to common antibiotics in a range of gastrointestinal disease. They found that the antibiotic resistance increased to more than two-fold over the past two decade. They presented the results recently at UEG Week Barcelona 2019.
The work looked at the resistance to clarithromycin, a common antibiotic, which forms a part of treatment regimen for Helicobacter pylori (H. pylori). The bacterium causes peptic ulcer disease and gastric cancer. Moreover, Tthe pathogen has been behind a host of complex diseases that call for a combination of strategies.
Novel Treatment Strategies for Preventing Death from Gastric Cancer
The study involved 1,232 patients across Europe. The findings highlighted that the rise in resistance rate from 1998 to 2018 by more than double— 9.9% to 21.6%. Furthermore, the researchers flagged the concern that with the increasing resistance—of almost 1% every year—there will an urgent need for novel treatments for peptic ulcer and gastric cancer. H. pylori affects one in every two worldwide, and the morbidity is evident in the growing deaths from gastric cancer. To put things in perspective, it is the seventh leading cause in Europe.
In fact, the WHO has highlighted this in 2017 and called for urgent action for better antibiotic-resistance containment strategies. Moreover, the study found that the number of deaths against antimicrobial resistance in a few countries in Europe are glaring. Future efforts must focus on prevention strategies.